Barcoded Telomerase Processivity Assay for Ultra-High-Throughput Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective way to screen for small molecules that enhance or inhibit telomerase activity, which is crucial for addressing aging and short-telomere diseases, while minimizing the risk of tumorigenesis in normal cells.
Innovation Solution
A rapid screening method using a bar-coding system and optimized telomerase primer-extension reaction conditions to analyze telomerase repeat addition activity and processivity in an ultra-high-throughput manner, allowing for the identification of agents that enhance or inhibit telomerase activity without promoting tumorigenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional DNA polymerase is used for DNA replication, then DNA synthesis occurs, but the 3'-end of linear DNA molecules cannot be fully replicated due to the end-replication problem
Solution Approach 1:
The patent employs telomerase, a specialized reverse transcriptase enzyme with unique properties (RNA template component, processivity factor associations) that differ from conventional DNA polymerases. This parameter change in enzyme type enables complete end-replication by allowing synthesis in the 5' to 3' direction using an RNA template, thereby solving the end-replication problem and maintaining telomere length
2Reliability
If telomerase activity is enhanced to treat aging and short-telomere diseases, then telomere length is maintained and cellular immortality is achieved, but there is a risk of promoting tumorigenesis in normal cells
Solution Approach 1:
The patent utilizes the selective expression pattern of telomerase as a local quality difference: telomerase is naturally active in stem cells and cancer cells but inactive in most normal somatic cells. By developing assays that measure telomerase processivity, the invention enables selective enhancement of telomerase activity in stem cells (where it is already present) without affecting normal cells (where it is absent), thereby maintaining telomere length in target tissues while avoiding tumorigenesis risk in normal tissues
3Measurement precision
If traditional screening methods are used to identify telomerase modulators, then compound evaluation is performed, but the screening throughput is limited and time-consuming
Solution Approach 1:
The patent replaces traditional mechanical/chemical screening methods with a molecular biology-based assay system. The invention uses telomerase primer-extension reactions followed by automated DNA sequencing to measure telomerase processivity. This substitution of measurement mechanics enables ultra-high-throughput screening capabilities, allowing evaluation of numerous compounds simultaneously while maintaining precise measurement of telomerase activity through sequence analysis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the screening of over 500,000 small molecules in less than 6 months, identifying drugs that specifically target telomerase in stem cells without affecting normal cells, thus providing safer anti-aging treatments and potential cancer therapies.
Implementation Method 1
Telomerase is a unique reverse transcriptase that specializes in telomeric DNA synthesis at chromosome ends. It contains two essential core components: the catalytic protein telomerase reverse transcriptase (TERT) and telomerase RNA (TR). The catalytic TERT protein synthesizes telomere DNA with a sequence specified by a short template sequence provided by the telomerase RNA component.
Implementation Method 2
The telomere sequences consist of tracts of tandemly repeated nucleotide sequences: (TTAGGG)n. In human cells, the length of telomeres varies dramatically from 5 to 15 Kb, depending on the cellular age. However, the mechanisms that control telomere length are not well understood.
Data Source
AI summary
The present invention provides methods and kits for determining telomerase processivity. These methods and kits may be used to screen for drugs that inhibit or enhance telomerase repeat addition activity, and are readily adapted to an ultra-high-throughput format.